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ABSTRACT
The protein p27Kip1 is a member of the Cip/Kip family of cyclin-dependent kinase 
(Cdk) inhibitors. It interacts with both the catalytic and the regulatory subunit (cyclin) 
and introduces a region into the catalytic cleave of the Cdk inducing its inactivation. 
Its inhibitory capacity can be modulated by specific tyrosine phosphorylations. 
p27Kip1 also behaves as a transcriptional regulator. It associates with specific 
chromatin domains through different transcription factors. ChIP on chip, ChIP-seq 
and expression microarray analysis allowed the identification of the transcriptional 
programs regulated by p27Kip1. Thus, important cellular functions as cell division 
cycle, respiration, RNA processing, translation and cell adhesion, are under p27Kip1 
regulation. Moreover, genes involved in pathologies as cancer and neurodegeneration 
are also regulated by p27Kip1, suggesting its implication in these pathologies.
The carboxyl moiety of p27Kip1 can associate with different proteins, including 
transcriptional regulators. In contrast, its NH2-terminal region specifically interacts 
with cyclin-Cdk complexes. The general mechanistic model of how p27Kip1 regulates 
transcription is that it associates by its COOH region to the transcriptional regulators 
on the chromatin and by the NH2-domain to cyclin-Cdk complexes. After Cdk 
activation it would phosphorylate the specific targets on the chromatin leading to 
gene expression. This model has been demonstrated to apply in the transcriptional 
regulation of p130/E2F4 repressed genes involved in cell cycle progression.
We summarize in this review our current knowledge on the role of p27Kip1 in the 
regulation of transcription, on the transcriptional programs under its regulation and 
on its relevance in pathologies as cancer and neurodegeneration.
INTRODUCTION
The protein p27Kip1 (p27) is a member of the Cip/
Kip family of cyclin dependent kinase (Cdk) inhibitors 
that also includes p21Cip1 (p21) and p57Kip2 (p57) [1]. 
The gene encoding human p27 (CDKN1B) is mapped 
to chromosome 12p13, contains 3 exons and encodes 
for a protein of 198 aa [2, 3]. These three proteins lack 
stable tertiary structure in isolation and are classified as 
intrinsically disordered proteins [4, 5]. Despite of that, 
they have several structured regions in their N-terminal 
domains [6]. These regions are included in the kinase 
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inhibitory domain (KID) that is conserved between 
these proteins. The KID consists of three subdomains: 
the cyclin-binding subdomain (D1), the Cdk-binding 
subdomain (D2) and a linker subdomain that joins D1 and 
D2 (LH) [7, 8]. In p27 the KID domain includes aa 28-
89 and contains a nuclear export signal (NES) (aa 32-46) 
(Figure 1A). In order to inhibit Cdk, a portion of the D2 
subdomain is introduced into the catalytic center of the 
Cdk. This portion competes with ATP thus blocking the 
transfer of phosphate to the substrates (Figure 2A) [9]. 
Whereas D1 and D2 are mostly unfolded in isolated p27 
they fold after binding to cyclins and Cdks. In contrast, LH 
is already structured as an α-helix before association with 
cyclin-Cdk and remains similarly folded after binding. In 
the region subsequent to the KID domain there is a proline 
rich domain (aa 90-96) known to interact with a variety 
of proteins as for instance the adaptor protein Grb2 [10]. 
The C-terminal domain (CTD) of p27 is an intrinsically 
disordered region that associates with a growing number 
of different proteins and contains a nuclear localization 
signal (NLS) (aa 152-168) (Figure 1A).
The cellular levels of p27 are regulated by both 
transcriptional and post-transcriptional processes. A 
number of transcription factors (TFs) including FKHR-L1, 
AFX, FOXO, Sp1, E2F1, and Menin have been identified 
as transcriptional activators of p27, whereas, in contrast, 
c-myc, Id3 and Ap1 act as transcriptional repressors 
[11–17]. However, it is assumed that the relevance 
of transcriptional regulation of p27 is low whereas in 
contrast, the main role in regulating cellular p27 levels 
is carried out by the control of its degradation [18, 19]. 
Specifically, p27 is mostly controlled by ubiquitin 
dependent-proteolysis which requires its phosphorylation 
or acetylation. Acetylation of p27 at K100, at mid G1 
phase of the cell cycle, by the acetyl transferase p300/
CBP associating factor (PCAF), has been shown to 
induce its ubiquitylation and subsequent degradation 
via proteasome in the cell nucleus [20] (Figure 1B). The 
phosphorylation of T187 by Cyclin-Cdk2 complexes also 
induces its degradation in the nucleus. Specifically, this 
phosphorylation is recognized by the F-box protein Skp2, 
a subunit of the SCF E3 ubiquitin ligase that triggers its 
ubiquitylation and subsequent degradation via proteasome 
(Figure 1B) [21]. Interestingly, phosphorylation of specific 
tyrosine residues in the D2 subdomain (Y74 and Y88 in 
p27), by different tyrosine kinases, including the Src 
family, allows the partial activation of the Cdk in the 
trimeric complexes formed by cyclin, Cdk and p27 due 
to a conformational change of this p27 domain (Figure 
2B) [22–26]. The partial activation of the Cdk allows to 
this Y-phosphorylated p27 to be efficiently phosphorylated 
at threonine 187 by the activated Cdk, which in turn 
promotes its Skp2 dependent degradation. Thus, specific 
tyrosine phosphorylation of p27 stablish a direct link 
between p27 Cdk-inhibitory activity and stability [22]. 
Interestingly, something equivalent happens with p21 [27].
Phosphorylation of p27 at S10 induces its 
translocation from nucleus to the cytoplasm (Figure 1B). 
This phosphorylation, mediated by different kinases as 
Cdk5, Akt or Kis, facilitates its binding to the carrier 
Figure 1: Representation of the key functional domains of p27 along with the most relevant post-translational 
modifications. (A) The N-terminal domain of p27 includes the kinase inhibitory domain (KID) that consists of three subdomains: the 
cyclin-binding subdomain (D1), the Cdk-binding subdomain (D2) and a linker subdomain that joins D1 and D2 (LH). This region also 
includes a nuclear export signal (NES). In the region subsequent to the KID domain there is a proline rich domain (PRD) (aa 89-96). The 
C-terminal domain of p27 is an intrinsically disordered region that contains a nuclear localization signal (NLS). (B) The most relevant sites 
of phosphorylation are represented in black. The specific site of acetylation (K100) is marked in red.
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protein CRM1 that transports p27 to the cytoplasm [28]. 
Once in the cytoplasm S10-phosphorylated p27 can be 
retained there by its phosphorylation at T157 and T198 
by different kinases like Akt, SGK or AMPK [11]. These 
phosphorylations are recognized by 14-3-3 proteins that 
sequesters p27 in the cytosol [29]. Interestingly, T157 is 
located in the NLS of p27 and its phosphorylation may 
impair its transport to the nucleus (Figure 1B). Once in 
the cytoplasm phosphorylated-p27 can be stabilized or in 
contrast, it can be degraded by the E3 ubiquitin ligases 
KPC1 and KPC2 [11].
Recent evidence indicate that p27 is involved 
in the regulation of cytoskeleton reorganization and 
gene expression [30]. It has also been reported that p27 
deregulation (decreased levels or cytoplasmic localization) 
might be involved in relevant pathologies as cancer and 
neurodegeneration [3, 31, 32]. In this review we aim to 
briefly summarize the role of p27 as a transcriptional 
regulator and its implication in these pathologies.
P27 REGULATES THE ACTIVITY OF 
MEMBERS OF THE CDK FAMILY
All the members of the Cip/Kip family have the 
ability to associate with a number of different cyclin-Cdk 
complexes and act by binding to both cyclins and Cdks 
[9]. The classical role of the Cip/Kip members is to inhibit 
the activity of most cyclin-Cdk complexes involved in cell 
cycle progression [33].
Cyclin-dependent kinases (Cdks) are serine/
threonine kinases whose activity depends on their 
association with specific regulatory subunits named 
cyclins [34]. Cdks include 20 kinases named as Cdk1 
through Cdk20 [35]. These kinases were initially 
described as essential drivers of cell cycle progression [36, 
37]. However, research performed during the last decades 
provided evidence that Cdks are also involved in gene 
transcription, DNA damage repair, cell differentiation 
and metabolism. Despite of these diversity of functions, 
Cdks have been classically classified into two main groups 
corresponding to Cdks involved in cell cycle regulation 
(Cdk1, Cdk4 and Cdk5 subfamilies) and to Cdks involved 
in transcription (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20 
subfamilies) although these activities are frequently 
combined in many family members [38]. Cdks are 
primarily activated by their binding to regulatory subunits 
named cyclins because their protein levels oscillate 
during the cell cycle [39, 40]. The cyclin family contains 
approximately 29 members in humans with a high spectra 
of molecular weights (35-90 kDa). Most of the Cdks bind 
one or a few cyclins consistent with specialized functions 
acquired during evolution [41].
Cdk activity is regulated by different mechanisms 
that include: 1) association with cyclins that activate 
Cdks, 2) an activating phosphorylation, 3) inhibitory 
phosphorylations, 4) inactivation by acetylation, and 5) 
association with inhibitory proteins. As mentioned above, 
the association of a Cdk with its cyclin partner is needed 
Figure 2: Regulation of p27 activity by phosphorylation. (A) To inhibit cyclin-Cdk activity, p27 associates with both, the cyclin 
subunit and the Cdk. A p27 portion is introduced into the catalytic center of the Cdk, This portion competes with ATP thus, blocking the 
transfer of phosphate to the substrates. (B) Phosphorylation of specific tyrosine (Y74 and Y88) residues of p27 by different tyrosine kinases 
(TK) generates a conformational change that separates the inhibitory region from the catalytic cleavage of the Cdk, leading to its partial 
activation.
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for a minimal activity. This activity is enhanced by the 
specific phosphorylation of a threonine residue (T160 in 
Cdk2) by the cyclin H-Cdk7 complex (Cdk-activating 
kinase (CAK)) that stabilizes the activated form of the 
Cdk [42]. Moreover, Cdk activity can be inhibited by 
phosphorylation of specific residues (Thr14 and Tyr 15 in 
Cdk2) by Wee1 and Myt1 kinases [43]. These phosphates 
can be eliminated by the action of phosphatases of the 
Cdc25 family thus re-inducing Cdk activity [44]. It has 
also been reported that the acetyltransferases GCN5 and 
PCAF, regulate CDK9 function by specifically acetylating 
the catalytic core of the enzyme and, in particular, a 
lysine that is essential for ATP coordination and the 
phosphotransfer reaction. This acetylation inhibits Cdk9 
activity [45]. Because this lysine is highly conserved in all 
the Cdks, it has been postulated that this may be a general 
mechanism involved in Cdk inhibition. In fact, a report 
showing that PCAF acetylates an equivalent lysine in 
Cdk2 inhibiting its activity supports this possibility [46]. 
Cdk activity can also be regulated by the association to 
inhibitory proteins that belongs to two families, the Ink4 
family and the Cip/Kip family. The ink4 family includes 
p16Ink4a, p15Ink4b, p18Ink4c and p19Ink4d [47]. These members 
act by specifically associating with Cdk4 and Cdk6 and 
thus blocking their interaction with the D-type cyclins. 
The aforementioned Cip/Kip family includes p21, p27 
and p57.
The extracellular signals regulating cell cycle 
trigger the activation of different pathways that finally 
act by regulating cyclin-Cdk activity through any of these 
different mechanisms. Also the intracellular cell cycle 




Transcriptional regulators as substrates of Cdks
In the current model of cell cycle regulation, the 
main targets of the G1 cyclin-Cdk complexes (Cyclin 
D-Cdk4/6 and cyclin-Cdk2) are the members of the pocket 
proteins family: the retinoblastoma protein (pRB), p130 
and p107 [48]. During the G1 phase of the cell division 
cycle, important genes involved in DNA replication (S 
phase) and in the subsequent phases of the cell cycle 
are repressed by complexes including pocket proteins 
and different members of the E2F transcription factors 
(TFs) family associated to DPs [49]. Specifically, the 
complexes pRB-E2F (1-3) and p130-E2F4 are associated 
to E2F binding sites on the chromatin regulatory regions 
of specific genes in quiescent cells. After proliferative 
activation active Cdk4/6 mono-phosphorylate both pRB 
and p130 [50, 51]. Later on, cyclin-Cdk2 complexes 
multi-phosphorylate pRB and p130 leading to their 
separation from the repressive complexes [50, 51]. Then, 
the repressor E2F4 moves out of the chromatin and 
translocate to the cytoplasm [52] whereas in contrast, the 
activators E2F1-3 remain in the chromatin and promote 
gene expression [53, 54].
In addition to these main targets, cyclin-Cdk 
complexes are able to phosphorylate a number of TFs 
thereby linking cell cycle and transcription [55]. Among 
them, it is specifically interesting the phosphorylation of 
FOXM1 and B-Myb since these TFs associate with the 
MuvB repressor complexes that regulate the expression of 
G2/M genes during cell cycle [49, 55]. TFs as Smad3, ID2, 
UBF, NFY and Myc are also phosphorylated by cyclin-
Cdk complexes regulating important cellular functions 
[56–60]. Since p27 regulates the activity of cyclin-Cdk 
complexes that phosphorylate these TFs, it becomes an 
important player in regulating transcription.
There are several Cdk subfamilies that are directly 
involved in the regulation of transcription (Cdk7, Cdk8, 
Cdk9, Cdk11 and Cdk20 subfamilies). The main role of 
these Cdks is to regulate the activity of RNA polymerase 
II (RNAPII) and this is performed by phosphorylating 
specific sites of the C-terminal domain (CTD) of the 
largest subunit (Rpb1) of RNAPII. Also cell cycle-related 
kinases Cdk1 and Cdk2 phosphorylate the CTD [61, 62]. 
Despite the ability of p27 to regulate the activity of these 
transcriptional Cdk subfamilies still remains obscure, 
its ability to inhibit Cdk1 and Cdk2 implies the direct 
regulation of transcription through this mechanism.
p27 as a transcriptional regulator
Quiescent cells have high levels of p27 in the 
nucleus. However, when cells are induced to proliferate, 
most of this nuclear p27 translocate into the cytoplasm 
where it is subsequently degraded. These facts suggested 
that p27 was playing a role in the nucleus of quiescent 
cells that had to be related to the inhibition of cell 
division cycle since proliferating cells needed to reduce 
or eliminate this nuclear p27. The identification of 
several chromatin associated proteins, as for instance 
the transcriptional co-activator PCAF, as p27-binding 
proteins strongly supported the putative role of p27 
in the regulation of transcription [20]. Previous 
evidences already suggested the participation of p27 in 
transcription. It was shown that the association of p27 
with the TF neurogenin-2 induces its stabilization and the 
differentiation of neural progenitors in the cortex [63]. It 
was also reported that p27 associates with the promoter 
of the Twist1 gene repressing its transcription [64]. The 
implication of p21, another member of the Cip/Kip family 
of Cdk inhibitors, in the regulation of transcription also 
reinforced the putative role of p27 as a transcriptional 
regulator. It was demonstrated that p21 interacts with 
and regulates the activity of various TFs as NF-κB, Myc, 
E2F, STAT3 and estrogen receptor [65–67]. Expression 
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microarray analysis confirmed that over-expression of 
p21 induced the repression of genes involved in cell cycle 
progression [68–70]. Interestingly, p21 associates with 
and regulates the activity of transcriptional co-activators, 
with acetyltransferase activity, as p300/CBP [71] thus, 
mediating transcriptional regulation also through this 
interaction [67]. A general correlation between the cell 
cycle dependent element (CDE) and the cell cycle gene 
homology region (CHR) sequences with the p21 inhibitory 
effects was also reported thus leading to the proposal that 
transcriptional regulation by p21 can be mediated by these 
chromatin sequences [70, 72].
p27 associates with chromatin and regulates 
transcription
The nuclear localization of p27 in quiescent cells and 
its interaction with chromatin-bound proteins suggested 
that p27 could be associated with chromatin and there to 
play a role as a transcriptional regulator. ChIP on chip 
analysis performed in quiescent NIH3T3 cells and directed 
to identify p27-binding sites (p27-BSs) on gene promoters 
firstly demonstrated that p27 specifically associates with 
427 gene promoters. This association was further validated 
in a number of genes by ChIP followed by qPCR [73]. 
Gene Ontology (GO) classification of these putative p27-
target genes (p27-TGs) revealed that p27 could participate 
in the regulation of genes involved in important cellular 
functions as RNA processing and splicing, translation, cell 
division cycle, respiration and Golgi vesicle transport. The 
evidence showing that p27 could regulate the expression 
of these genes were obtained from expression microarray 
analyses performed in quiescent mouse embryonic 
fibroblasts (MEFs) from WT and p27 knock out (p27KO) 
animals. Results revealed that a significant number of 
the previously identified p27-TGs were up-regulated in 
p27KO cells indicating a transcriptional repressor role of 
p27 [73]. MEFs harboring different p27 mutants unable to 
associate with cyclin–Cdk complexes (the p27Δ51 mutant 
that has a deletion of the first 51 aa and the p27CK- mutant 
including mutations in the regions of interaction with 
cyclins and Cdks [74, 75]) also showed a significant up-
regulation of p27-TGs [73]. Interestingly, most of the up-
regulated genes overlapped in these different cell types 
[73]. In all these cells, Cdk activities are high since p27 
is not operative as a Cdk inhibitor. Thus, these results 
indicate that the Cdk inhibitory ability of p27 is essential 
for the repression of transcription. Intriguingly, cells 
with the p27CK- mutant additionally showed a significant 
number of down-regulated p27-TGs that were not 
decreased in p27KO or p27Δ51 cells [73]. These results 
revealed that the transcriptional regulatory role of p27 can 
proceed through different mechanisms but that inhibition 
of cyclin-Cdks is essential for gene repression in at least a 
significant number of p27-TGs [73].
Two different articles have reported ChIP-seq 
analyses that have been performed to identify the p27-
BSs in the chromatin of two different cellular types. One 
has been performed in quiescent HCT116 colorectal 
cancer cells [76] and the other one in quiescent MEFs 
[77]. In HCT116 cells, 1981 specific p27-BSs that 
were annotated to 1012 genes were identified (Table 1). 
Similarly, in MEFs, 1839 p27-BSs were detected. In this 
case they were annotated to 1417 genes. These results 
indicate that in some cases more than one p27-BSs was 
annotated to a specific gen. These studies also revealed 
that in both cellular types only a small number of p27-
BSs were on gene promoters while most of them were 
in distal intergenic (74% and 64%) or intronic regions 
(24% and 31%). Another interesting observation was 
that a significant number of p27-BSs (~40% in both 
cases) were close to pseudogenes or sequences of non-
coding RNAs suggesting a role of p27, not only in the 
transcriptional regulation of protein encoding genes, but 
also of pseudogenes and non-coding RNAs [76, 77]. 
Specifically, a significant number of microRNAs (Mirs) 
were annotated to p27-BSs in both cellular types. Most 
of these Mirs are different in these cellular types being 
mir-214 the only one shared between the two cell types. 
Mir-214 is involved in tumorigenesis in different types 
of cancer and it has been proposed to be useful as a 
cancer biomarker [78]. Most of the other Mirs that can 
be putatively regulated by p27 (unpublished results) are 
also involved in cancer. Interestingly, also a number of 
small nucleolar RNAs (snoRNAs) were annotated to 
p27-BSs in both types of cells. They belong to the two 
groups (H/ACA and C/D) that promote pseudouridylation 
and methylation, respectively of the pre-ribosomal RNA 
but also of pre-mRNA [79]. It has been reported that 
deregulation of different snoRNAs expression is involved 
in neurodegeneration and cancer [80, 81].
These ChIP-seq analyses also revealed that 
7SK RNA can be putatively regulated by p27. This 
RNA regulates the activity of P-TEFb that stimulates 
transcriptional elongation [82]. Finally, the five major 
spliceosomal RNAs (U1, U2, U4, U5, U6 and U7) [83] are 
also found annotated to specific p27-BSs, suggesting that 
p27 might regulate splicing by controlling the expression 
of these RNAs. Thus, the putative regulation of these 
different types of non-coding RNAs by p27 has to be taken 
into account in the next future to better understand the role 
of p27 in tumorigenesis, neurodegeneration and perhaps 
other pathologies.
Remarkably, GO classification of the protein 
encoding genes putatively regulated by p27 revealed that 
in both cellular types, the four more significant biological 
processes were cell adhesion, neuron differentiation, cell 
signaling and ion transport (Figure 3). The transcriptional 
regulation of a number of these putative p27-TGs by p27 
was further validated by qPCR in both cellular types.
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Taken together all these results indicate that the 
role of p27 in transcription is mostly performed by 
its association to chromatin regions distal from gene 
promoters and intronic regions. The genes putatively 
regulated by p27 through the interaction with these 
regions are preferably involved in the four biological 
processes mentioned above. However, despite the global 
association of p27 with gene promoters seems to be 
limited, the ChIP on chip analysis performed in NIH3T3 
cells indicates that several relevant cellular functions as 
cell cycle progression, mRNA processing and splicing, 
translation and respiration are regulated by the p27 
association with specific gene promoter sequences. A 
possible interpretation of these data may be that different 
sets of genes can be regulated by the association of p27 to 
different chromatin domains.
Table 1: ChIP-seq data obtained from experiments in two different cell lines using anti-p27 antibodies
Cell type p27-BSs Genes Distal intergenic Intronic promoters
HCT116 1981 1012 74% 24% 0.3%
MEFs 1839 1417 64% 31% 0.8%
Table summarizes the cell types used, the number of p27-binding sites (p27-BSs) identified, the number of genes to which 
these p27-BSs were annotated and the percentage of p27-BSs associated to distal intergenic, intronic or promoter regions.
Cell type Protein ncRNAs Pseudogenes
HCT116 59% 23% 18%
MEFs 60% 28% 12%
Table summarizes the cell types used in the ChIP-seq analysis and the biotypes corresponding to the annotated genes. 
Specifically, the table includes the percentages of annotated protein encoding genes (protein), non-coding RNAs (ncRNAs) 
and pseudogenes.
Figure 3: Gene ontology analysis of protein encoding genes with p27-BSs in their proximity. ChIP-seq analysis using p27-
antibodies were performed in HCT116 and MEFs cells. The Database for Annotation, Visualization and Integrated Discovery (DAVID) 
program was used to define biological processes enriched in the protein encoding genes putatively regulated by p27. The number of genes 
included in each biological process is represented.
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Specific TFs mediate the transcriptional 
regulatory role of p27
There is no evidence for p27 directly associating 
with DNA, thus its interaction with the chromatin has to 
be through chromatin-binding proteins. The identification 
of the p27-binding proteins that mediate its association 
with chromatin was firstly achieved by sequence analysis 
of the p27-BSs on the promoters detected by ChIP on chip 
[73]. This analysis was directed to determine whether in 
these p27-BSs there were consensus sequences for TFs. 
Results revealed that these p27-Bs were enriched with 
regions able to associate with E2F4 and several members 
of the ETS family of TFs as for instance ETS1 and GABP. 
Immunoprecipitation (IP) and ChIP experiments further 
confirmed that actually p27 associate with specific gene 
promoters through its binding to E2F4 or ETS1 [73]. 
Subsequent sequence analysis of the p27-BSs identified 
by ChIP-seq in HCT116 cells showed that Pax5 could also 
be a partner of p27. The interaction of PAX5 with p27 
was further validated by IP [76]. Finally, sequence analysis 
of the p27-BSs identified by ChIP-seq in MEFs revealed 
enrichment of several TFs as AHR, Ap2α and Ap2γ, 
Pax5, Pax4, and MyoD, among others. The association of 
p27 with some of these TFs was subsequently validated 
by IP [77]. Thus, p27 plays a role in the regulation of 
transcription by associating with a significant number 
of different TFs (Figure 4). Probably, the complexes of 
p27 with each one of these TFs may be involved in the 
transcriptional regulation of specific subset of genes. 
For instance, the association of p27 with E2F4 or with 
ETS on specific gene promoters can be involved in the 
transcriptional regulation of G1/S cell cycle related genes 
[73] whereas its association with Pax5 in distal intergenic 
regions can participate in the regulation of genes involved 
in cell adhesion, cell signaling, ion transport and neuron 
differentiation [76].
Interestingly, the analysis of the p27-TGs, identified 
in the ChIP on chip studies, whose expression is altered in 
cells lacking p27 or in cells with the different p27 mutants 
gave interesting information [73]. It was observed that in 
p27KO MEFs the p27-TGs that were up-regulated were 
those mediated by ETS TFs. In contrast, those repressed 
by p130/E2F4 were not modified in these cells. These 
data suggest that p27 is an inhibitor of ETS activity and 
thus, in the absence of p27, ETS can activate transcription. 
Intriguingly, in contrast to that observed in p27KO cells, 
in p27Δ51 and p27CK- - MEFs the genes repressed by p130/
E2F4 were up-regulated [73]. These results indicate that 
the presence of the carboxyl moiety of p27 in the cells 
is necessary to activate the expression of p130/E2F4 
dependent genes [73]. Another interesting result is that 
in p27CK- - MEFs a significant number of p27-TGs was 
down-regulated. Remarkably, these down-regulated genes 
were ETS-dependent [73]. Surprisingly, this repression 
only happened in these cellular type, since p27KO and 
p27Δ51 did not show the down-regulation of these p27-
TGs [73]. These results can be interpreted as that the 
first 51 aa contain a co-repressor sequence that when lost 
facilitates transcription (by eliminating the sequence, in 
the case of p27Δ51 or when p27 is absent in the p27KO). 
In contrast, when this sequence is present (p27WT) 
and able to associate the cyclin and Cdk complexes, 
transcription is temporally regulated [73]. However, in 
the case of p27CK-, it may be postulated that despite the 
first 51 aa are present, the mutated form of this fragment, 
that prevents its association with cyclin-Cdks, might adopt 
a conformation that totally unable the accessibility of 
cyclin-Cdk complexes to phosphorylate the transcriptional 
regulators on the promoters. In this case it additionally 
plays a role as a strong repressor.
p27 regulates transcription of p130/E2F4 
repressed genes
Detailed investigations have been performed 
to analyze the mechanisms by which p27 regulates 
transcription through E2F4. In quiescent cells E2F4 
mainly associates with p130 to form transcriptional 
repressor complexes on promoters of genes involved 
in cell cycle progression [48, 84, 85]. These complexes 
additionally include several co-repressors as different 
HDACs and mSin3A [86, 87]. In these complexes E2F4 
directly associates with specific DNA sequences although 
its interaction requires p130. In the absence of p130 (that 
does not directly bind to DNA) E2F4 cannot interact with 
these specific DNA sequences [87]. These complexes 
mainly act by repressing, during the G1 phase of the cell 
cycle, the expression of genes encoding proteins needed 
for DNA replication and the subsequent phases of the cell 
cycle. However, in cells suffering DNA damage, these 
complexes might also act by repressing G2/M genes 
[88, 89] and genes involved in DNA repair as RAD51 
and BRC1 [88, 90]. Moreover, other genes not directly 
involved in cell cycle progression as for instance Sox2 
and α-synuclein (α-SYN) can be also repressed by these 
complexes [91, 92].
IP experiments demonstrated that p27 interacts 
with members of these complexes as p130, E2F4, several 
HDACs and mSin3A [73]. Moreover, it has also been 
shown that p27 directly interacts with E2F4 and p130 
through specific domains located in its carboxyl moiety 
[73]. These interactions allow p27 to participate in these 
repressor complexes on the promoters of specific target 
genes. As mentioned above, p130 is a key protein to 
maintain these repressor complexes on the promoters since 
the interaction of E2F4 with DNA depends on p130. This 
is the reason why phosphorylation of p130 by specific 
cyclin-Cdk complexes during G1 promotes the disruption 
of p130-E2F4 interaction thus allowing E2F4 to move out 
of the promoters and facilitating transcription.
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Interestingly, the association of p27 with the 
promoters depends on p130. In fact, in p130 KO cells, p27 
is not able to interact with these regulatory regions [73]. 
This association that is through its carboxyl tail, permits 
p27 to have its NH2 regions, involved in the interaction 
with cyclins and Cdks, accessible to associate with these 
complexes. This is compatible with the simultaneous 
association of p27 with the promoters through p130/
E2F4 by its COOH tail and with cyclin-Cdk by its NH2 
terminal domain (Figure 5). Since p130 is a classical 
substrate of Cdks it has been postulated that in fact, one of 
the roles of p27 could be to recruit cyclin-Cdk complexes 
on the promoters of target genes at early-mid G1. This 
recruitment would allow to place these complexes 
very close to its substrate p130 and thus facilitating its 
phosphorylation when the Cdk becomes active (Figure 
5). The fine regulation of cyclin-Cdk activity by p27, on 
depending of its tyrosine phosphorylation status, would 
also precisely define the timing of Cdk activation and as 
a consequence the moment of the cell cycle in that p130 
should be phosphorylated.
ChIP experiments performed at different times 
after proliferative activation allowed to generate a model 
describing the basic mechanisms through which p27 
regulates the transcription of genes repressed by p130/
E2F4 complexes during the G1 phase of the cell cycle 
[93]. Since these genes are key for the progression of 
proliferation this mechanism provides fundamental data 
to understand the role of p27 in this process. We describe 
here this model as illustrated in Figure 5.
In quiescent cells, p27 is associated with the 
promoters of target genes bound directly to E2F4 and 
p130 by its carboxyl terminus. Simultaneously, cyclin D2/
D3-Cdk4 are bound to the KID domain of p27, sited on 
its amino moiety. At that time, Cdk4 activity is inhibited 
(Figure 5.1). When cells are induced to proliferate by a 
mitogenic stimulus, members of the Src protein kinase 
family or other tyrosine kinases can phosphorylate p27 
at Y74 and Y88, also when it is associated with cyclin-
Cdk complexes [22]. These phosphorylations induce a 
conformational change that reduce the inhibitory capacity 
of p27, thus allowing cyclin D2/D3-Cdk4 complexes to be 
active, despite being bound to p27 [94–96]. Active Cdk4 
associated with p27 located on the promoters of p27-TGs 
could then phosphorylate p130. This phosphorylation 
primes p130 for further phosphorylation by Cdk2. (Figure 
Figure 4: Regulation of transcriptional activity by p27 is mediated by its association with different transcriptional 
regulators. To regulate transcription p27 associates with different transcriptional regulators including TFs as p130/E2F4 complexes, Ap2, 
Pax4, Ets1, AHR, Neurogenein-2 (Ngn2), MyoD and Pax5. It also interacts with the transcriptional co-activator and acetyltransferase p300/
CBP associating factor (PCAF). The biological functions putatively regulated by these TFs and p27 are indicated.
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5.2). Once p130 has been phosphorylated at mid-G1 
phase, cyclin D2/D3-Cdk4 complexes must be removed 
from the promoters to allow the cyclin-Cdk2 entry to 
subsequently phosphorylate p130.
Removal of cyclin D2/D3-Cdk4 complexes from the 
promoters can be achieved by degrading p27, since these 
complexes are associated to the promoters through p27. 
Several mechanisms can participate in this elimination of 
p27. It has been shown that phosphorylation in Y74 and 
Y88 of p27 by tyrosine kinases allows the activation of 
the associated cyclin D-Cdk4 complexes that furtherly 
can phosphorylate T187 of p27 inducing its subsequent 
degradation [22]. Additionally, it has also been shown 
that, at G1, the acetyl transferase PCAF acetylates p27 
at its K100 inducing its ubiquitylation and subsequent 
degradation (Figure 5.3) [20]. It has been recently reported 
that PCAF can also facilitate the nuclear translocation of 
the Cdk4/6 inhibitor p16Ink4a and inducing Cdk4 inhibition 
[97]. Thus, a combination of these mechanisms induces 
p27 degradation and Cdk4 inactivation at mid G1. This 
p27 degradation facilitates the release of cyclin D2/
D3-Cdk4 from the promoters, although p130/E2F4 still 
would remain there since the association of E2F4 with the 
promoters depends on p130 (Figure 5.4).
The analysis of the mechanism of how cyclin-Cdk2 
complexes are incorporated to the promoters revealed 
that p21 plays an important role in this process [93]. In 
fact, when p27 moved out from the promoters at mid-
late G1, p21 associates with p130/E2F4. Remarkably, the 
association of cyclin D1 and Cdk2 with the promoters 
was also observed at that time (Figure 5.5). In fact, 
the association of cyclin D1-Cdk2 with the promoters 
is depending on p21 and p21KO cells are not able to 
incorporate them on these specific regulatory regions 
[93]. Cyclin D1-Cdk2 is a non-canonical complex that 
has been reported to exist in many different cellular 
types [98–101]. Interestingly, it has been shown that the 
association and activation of cyclin D1-Cdk2 complexes 
are highly dependent on p21 that acts as an assembly 
factor. In contrast, p27 is a very poor assembly factor for 
these complexes [102]. All these results indicate that p27 
and p21 collaborate in the regulation of transcription of 
genes repressed by p130-E2F4 acting as modulators of 
Cdk activity on the promoters.
At mid-late G1 of the cell cycle p27-cyclin D2/D3-
Cdk4 complexes are substituted by p21-Cyclin D1-Cdk2 
(Figure 5.5). At that point, Cdk2 is inactivated by p21, but 
the subsequent phosphorylation of p21 at Y77 (in human 
cells) by different tyrosine kinases induce, similarly to 
p27, a reduction of the capability to inhibit Cdk2 (Figure 
5.6) [27]. Thus, the activated Cdk2 on the promoters 
can then multi-phosphorylate p130. Additionally, Cdk2 
phosphorylates p21 at S130 that induces its degradation 
[27]. These phosphorylations induce the disruption of the 
repressor complexes and as a consequence the promoter 
is free to bind transcriptional activators as E2F1 that will 
induce the transcription of target genes involved in DNA 
replication and cell cycle progression. (Figure 5.7).
Interestingly, the expression kinetics of p27 and 
p21 during cell cycle progression is quite complementary. 
Whereas in G0 the amount of p27 is high, it subsequently 
decreases at early-mid G1 due to its degradation. However, 
the p21 levels that are very low in quiescent cells started 
to increase just when p27 was decreasing at early-mid 
G1. These different kinetics are due to the fact that p27 
regulates the expression of p21 through the TF Pitx2. It 
has been shown that p27 represses Pitx2 expression, thus, 
when p27 is degraded, Pitx2 expression increases and 
since it is a transcriptional activator of p21, it started to 
rise at that time [32]. This explains why p21 participates in 
the recruitment of cyclin D1-Cdk2 complexes at mid-late 
G1 and not before.
It has to be taken into account that in cells 
lacking p27, at early G1, cyclin-Cdk complexes could 
be active, although not recruited on the promoters, and 
able (perhaps with low efficiency) to phosphorylate 
p130. In such scenario, transcription of target genes 
would be facilitated and as a consequence also cell cycle 
progression. This p130 phosphorylation can occur unless 
p21 was upregulated due to the absence of p27. In this 
case p21 could inhibit cyclin-Cdk complexes and block 
transcription or p130/E2F4 repressed genes or at least to 
delay it. This phenomenon, can explain why in p27KO 
cells only the up-regulation of Ets-dependent genes was 
observed in the expression microarrays. Up-regulation of 
p21 would block transcription of p130/E2F4 depending 
genes. Thus, the simultaneous deletion of p27 and p21 
strongly induce transcription of targets genes. In this case 
cyclin-Cdk complexes would be not inhibited and would 
be more efficient to phosphorylate p130 [93].
Collaboration between p27 and PCAF in 
transcriptional regulation
It has also been extensively studied the 
collaboration between p27 and the co-activator PCAF. 
The acetyltransferase PCAF [103] has been shown to 
acetylate a number of proteins involved in cell cycle 
regulation. Specifically, It acetylates specific lysine 
residues in the catalytic center of Cdk9 and Cdk2 inducing 
their inactivation [45, 46]. Since Cdk9 associates with T 
cyclins and participates in the regulation of transcription 
by phosphorylating RNA polymerase II, its inactivation 
induces a transcriptional block. Similarly, PCAF 
also acetylates lysine residues in Cdk2 leading to its 
inactivation and thus slowing cell cycle progression. 
Interestingly, PCAF also acetylates cyclin A at specific 
lysine residues that stimulates its ubiquitylation and 
its subsequent degradation [104, 105]. PCAF can also 
facilitate the nuclear translocation of the Cdk4/6 inhibitor 
p16Ink4a and inducing Cdk4 inhibition [97]. Thus, PCAF 
that is considered a transcriptional co-activator also 
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Figure 5: Model of the role of p27 and p21 in the transcriptional regulation of p130/E2F4 repressed genes. In quiescent 
cells p27 is associated with p130 and E2F4 on the promoters of target genes by its COOH- moiety. It is also bound to cyclin D2/3 and Cdk4 
by is NH2-half. At this stage, Cdk4 is inactive due to its inhibition by p27 (1). At early-mid G1 phase of the cell cycle p27 is phosphorylated 
by tyrosine kinases at residues Y74 and Y88. These phosphorylations allow retrieving Cdk activity and thus Cdk4 can phosphorylate p130 
(2). Moreover, Cdk4 phosphorylate T187 of p27 facilitating its degradation. Degradation is also stimulated by the acetylation of K100 by 
the acetyltransferase and transcriptional co-activator PCAF (3). Degradation of p27 leads to the removal of cyclin D2/3 and Cdk4 from the 
promoters (4). After that, p21 associates with p130/E2F4 by its carboxyl terminus and recruits to the promoters cyclin D1-Cdk2 complexes 
that are associated with its NH2-moiety (5). After phosphorylation of the Y77 (in human) of p21, Cdk2 becomes activated and able to 
multi-phosphorylate p130. Cdk2 also phosphorylates S130 of p21 leading to its degradation (6). Phosphorylation of p130 and degradation 
of p21 disrupt the repressive complexes thus, allowing the action of activator transcription factors as E2F1 that initiate transcription of 
target genes (7).
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participates in regulation of cell cycle progression by at 
least three different mechanisms, by degrading cyclin A 
and by inactivating Cdk4 and Cdk2 all of them involved in 
the onset and progression of DNA synthesis [106].
Recently, it has been found that PCAF is also able 
to acetylate p27 at lysine 100. This acetylation induces its 
ubiquitylation and its degradation via proteasome. During 
cell cycle PCAF acetylates p27 mostly at early G1 and this 
acetylation participates in p27 degradation observed at that 
time [20]. This degradation of p27 facilitates the removing 
of cyclin D2/D3-Cdk4 from the promoters of target genes 
as mentioned above (Figure 5). Thus, altogether these 
data indicates that PCAF plays a role as facilitating cell 
cycle progression by degrading p27 and blocking Cdk4 
activity (when it is not needed) at mid G1. Later on during 
cell cycle, the induction of Cyclin A degradation and 
blocking Cdk2 by PCAF facilitates mitosis entry [107]. 
The transcriptional programs regulated by PCAF and p27 
in the colon cancer cell line HCT116 have been recently 
analyzed by ChIP-seq [76]. 269 protein-encoding genes 
were found to contain both p27 and PCAF-BSs in their 
vicinity. The majority of these sites were different for 
PCAF and p27 indicating the existence of specific distinct 
chromatin regions able to associate with PCAF or p27. 
PCAFKO or p27KO cells showed that both regulate the 
expression of these genes, PCAF as an activator and p27 
as a repressor. The double knock down of PCAF and p27 
strongly reduced the expression of these genes, indicating 
that the activating role of PCAF overrides the repressive 
effect of p27. Interestingly, the transcription factor Pax5 
interacts with both p27 and PCAF and its knock down 
induces the expression of p27/PCAF-TGs indicating that it 
also participates in the transcriptional regulation mediated 
by p27/PCAF [76].
Transcriptional programs regulated by p27
A first approach to the identification of the 
transcriptional programs regulated by p27 was the analysis 
of the genes, whose promoters included specific p27-BSs, 
identified by ChIP on chip and that were functionally 
classified by GO analysis [73]. Results indicated that the 
more significant biological processes were: 1) mRNA 
processing and splicing, 2) translation, 3) cell division, 4) 
mitochondrial organization and respiration and 5) Golgi 
vesicle transport. These results suggested that p27 could 
be directly involved in the regulation of important cellular 
functions.
A recent expression microarray analysis performed 
in p27KO-MEFs versus controls deeply amplified the 
functional aspects that could be regulated by p27 [32]. 
Specifically, the expression of 4022 genes were altered 
in p27KO-MEFs, 1844 up-regulated and 2178 down-
regulated. GO and KEGG pathway analysis of the 
altered genes indicated that four of the five biological 
processes observed to be regulated by p27 in the ChIP on 
chip experiments: mRNA processing and splicing, cell 
division, mitochondrial organization and respiration and 
Golgi vesicle transport were confirmed to be regulated by 
p27. Moreover, the expression data also confirmed results 
obtained by ChIP-seq revealing that the main biological 
processes putatively regulated by p27 as observed by 
ChIP-seq studies: cell adhesion, neuron differentiation, 
cell-cell signaling and ion transport were also represented 
in the expression microarrays. Interestingly, all these 
studies coincide in that the most significant biological 
process regulated by p27 is cell adhesion. A KEGG 
pathway analysis of data from the expression microarray 
showed different categories involved in cell adhesion 
as: extracellular matrix-receptor interaction, adherens 
junction, focal adhesion, gap junction and tight junction 
with a total of 103 genes, involved in cell adhesion, 
deregulated in p27KO cells [32]. This analysis confirms 
that cell adhesion is a major biological process regulated 
by p27 and this merits to be analyzed in detail in the next 
future. A recent report showing that cells lacking p27 have 
a much higher adherence to the culture plates than control 
cells, strongly support this concept [77].
In addition to that, the KEGG pathway analysis of 
the expression data revealed a number of very interesting 
pathways putatively regulated by p27. For instance, in 
addition to those mentioned above, metabolic pathways 
as glutathione metabolism, purine and pyrimidine 
metabolism, fatty acid metabolism, pyruvate metabolism 
and amino acid metabolism are also regulated by p27. 
Other functions as axon guidance, mismatch repair and 
nucleotide excision repair are as well under the control 
of p27. Another very interesting aspect is that cells 
lacking p27 deregulates a significant number of genes 
involved several pathologies as cancer and different 
neurodegenerative diseases as Huntington’s disease, 
Alzheimer’s disease and Parkinson’s disease [32].
Finally, it is important the fact that in the absence 
of p27 a significant number of TFs are deregulated. 
Specifically, the up-regulation (> 3 fold change) of 42 
TFs and the down-regulation (> 3 fold change) of 24 
TFs was observed in p27KO cells. The alteration of TF 
expression in p27KO cells could be responsible for most 
of the expression changes observed in these cells [32]. The 
analysis of this list revealed that TFs regulated by p27 are 
involved in important biological functions. As examples, 
seven Hoxa genes (Hoxa1-Hoxa7) belonging to a cluster 
involved in embryo development [108] are up-regulated in 
p27KO MEFs suggesting a role of p27 in this process [32]. 
p27 can also participate in patterning and morphogenesis 
because three of the five Zic homologs (Zic1, 2 and 5) 
[109] are upregulated in cells lacking p27 [32].
Alteration of TF expression in p27KO brings 
up the possibility that the around of 4000 genes whose 
expression is altered in these cells could be a consequence 
of different transcription waves. First, a limited number 
of genes directly regulated by p27 would be initially 
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expressed in p27KO cells, and among them, some TFs, 
as for instance Mef2c, Sox6, Zfpm2 and Shox2 that have 
p27-BSs in their vicinity [77]. As a consequence, a second 
transcriptional wave can de generated by the action of 
these TFs. A number of successive transcriptional waves 
can be produced thus significantly amplifying the number 
of genes differentially expressed in p27KO cells.
Remarkably, p27 may be also involved in splicing. 
A number of specific splicing factors are deregulated in 
p27KO cells (unpublished results). Interestingly, these 
results together with those mentioned above regarding the 
putative regulation of the five major spliceosomal RNAs 
by p27 suggest an unexpected new role of p27 in this 
relevant cellular process. However, this putative new role 
of p27 still remains unexplored.
Role of p27-mediated transcriptional regulation 
in Cancer
It is very well described that in many different types 
of human cancer the decrease of p27 or its cytoplasmic 
localization is associated with increased malignancy and 
with a worse outcome [110–114]. Initially, it was assumed 
that this correlation could be due to the fact that reduced 
levels of p27 would be unable to efficiently inhibit cyclin-
Cdk activities thus the high activity of these kinases would 
stimulate cell proliferation. However, the new role of p27 
as a transcriptional regulator suggested the possibility 
that in addition to the effect of p27 decrease on cell cycle 
progression by non-inhibiting cyclin-Cdk complexes, the 
reduction of p27 would also induce the deregulation of 
genes that could play a role in tumorigenesis and increased 
malignancy. In fact, in several cases, it has been stablished 
a correlation between p27 levels, expression of p27-
TGs and decreased survival [73]. On the other hand, the 
cytoplasmic location of p27 would alter the expression 
of genes under p27 regulation since transcription is a 
nuclear function. Additionally, in the cytoplasm p27 
plays an oncogenic role by activating cell motility and 
invasion through modifying the cytoskeleton functions. 
Specifically, in the cytosol, p27 can associate with RhoA, 
preventing its activation and thereby modulating actin 
cytoskeleton dynamics and migration [115, 116]. Thus, 
p27KO-MEFs have higher RhoA activity, increased 
numbers of stress fibers and focal adhesions and exhibit 
a defect in migration [116]. p27 regulates cell migration 
also by controlling microtubule stability through stathmin 
or directly by binding to microtubules and promoting 
microtubule polymerization [117]. It also represses lipid 
raft trafficking in a stathmin - dependent way. [118]. 
More recently, cytoplasmic p27 was reported to promote 
epithelial to mesenchymal transition by binding to JAK2, 
promoting STAT3 activation and the upregulation of 
Twist1 [119]. This cytoplasmic behavior of p27 related 
with cell motility has to be coordinated with the expression 
of genes involved in cell adhesion that as mentioned above 
are regulated by p27. Thus, during cell cycle progression 
when p27 moves from nucleus to the cytoplasm the 
simultaneous actions of p27 in the cytoplasm and the 
modifications in the expression of genes under the control 
of p27 may account for the changes in cytoskeleton 
activities, cell motility and adhesion. This coordination in 
normal cells is probably altered in cancer cells with low 
levels of p27 or with anomalous cytoplasmic localization. 
So, the role of p27 as a transcriptional regulator might 
play a relevant role in defining malignancy in tumors. 
Analysis of the expression microarrays data reveals that 
the decreased levels of p27 might deregulate a number of 
genes encoding proteins that participate in the progressive 
acquisition of biological capabilities by tumors and that 
define the different hallmarks of cancer [32, 73]. The 
hallmarks of cancer include 8 biological capabilities 
acquired during the multiple step development of human 
tumors. They include sustained proliferation, avoiding 
growth suppressors, avoiding immune destruction, 
deregulating cellular energetics, resisting cell death, 
inducing angiogenesis, enabling replicative immortality 
and activating invasion and metastasis. Underlying these 
hallmarks are also genome instability that generates the 
genetic diversity that expedites their acquisition and 
inflammation, which fosters multiple hallmark functions 
[120, 121].
The expression microarray data reveal that decreased 
levels of p27 might deregulate the expression of genes 
involved in at least four of these cancer hallmarks (Figure 
6). One of these Hallmarks is sustained proliferation. Due 
to its role as a Cdk inhibitor, the decrease of p27 levels 
will induce an increase in the activity of cyclin-Cdk 
complexes. Nevertheless, in addition to that it has to be 
considered that a number of different genes involved in 
cell proliferation are found deregulated in p27-deficient 
cells. These deregulated genes include: growth factors, 
growth factor receptors, proteins that participate in 
different signaling pathways as G-proteins, adenylate 
cyclases, phosphodiesterases, different MAPKs and more 
specifically as mentioned above, the genes involved in 
DNA replication that are under the control of p130/E2F4 
repressor complexes. It merits to specifically mention that 
different members of the Notch and Wnt pathways are also 
upregulated [32]. Thus, the decrease of p27 will foster 
proliferation by deregulating the expression of different 
signaling pathways.
The decrease of p27 levels can also facilitate the 
acquisition of a second hallmark: deregulating cellular 
energetics. Specifically, it has been shown that at least 
18 genes involved in oxidative phosphorylation and 
belonging to different complexes of the respiratory chain 
are down-regulated in p27KO cells. Interestingly, seven 
of these genes belongs to complex I. Thus, these results 
suggest that in p27-deficient cells there is a decrease of 
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oxidative phosphorylation. The decrease of respiration 
is a key mechanism leading to aerobic glycolysis, a 
characteristics of tumor cells [122–124]. In addition to 
that, alterations in a diversity of metabolic enzymes have 
also been observed [32]. Moreover, it is known that the 
reduction of respiration of cells in a normoxic environment 
induce oxidative stress. In these p27 KO cells oxidative 
stress cannot be efficiently controlled because there is 
also a significant down-regulation of at least 15 enzymes 
involved in glutathione metabolism. These data suggest 
that the detoxifying mechanism involving glutathione 
should be scarcely effective in these cells [32].
A number of cytokines and chemokines are 
upregulated in p27KO cells. Interestingly, some of these 
chemokines as CXCL1 and CXCL5 act through the 
binding to the CXCR2 receptor that has been involved 
in angiogenesis, invasion and metastasis [125–127]. 
Thus, p27 reduction would participate in invasion and 
metastasis through deregulation of these chemokines but 
also angiogenesis would be stimulated.
Tumors are thought to arise from mutant stem 
cells in their native niches. These niches are rich in 
developmental and self-renewal signals, among them Wnt 
and TGF-β [128, 129]. Also, their derived progenitors 
that retain the tumor-initiating capacity and that benefit 
from these niche signals can also generate tumors [130, 
131]. After dissemination, cancer stem cells interact with 
specialized niches that supports their survival and tumor-
initiating potential [132]. These disseminated tumor cells 
(DTCs) locate themselves in different supportive niches, 
similar to those that support normal adult stem cells 
[133]. Additionally, DTCs can set up an ad hoc niche by 
producing specific components as for instance tenascin 
C, that amplifies Notch and Wnt signaling, TGF-β, which 
stimulates fibroblasts to secrete periostin, and Procollagen-
Lysine, 2-Oxoglutarate 5-Dioxygenase 2 (Plod2) [134–
136]. All these components facilitate survival of DTCs 
thus favoring metastasis. Interestingly, all these proteins 
of the ad hoc niche are under transcriptional repression 
by p27 [32]. Thus, low levels of p27 would increase the 
expression of these genes and in such a way facilitate DTC 
survival and as a consequence metastasis. Finally, a recent 
report indicates that the TF Sox2 which is transcriptionally 
repressed by p27 and p21 [91, 137] plays a key role in 
triggering tumor initiation and cancer-stem cells functions 
in squamous-cell carcinoma. The targets of Sox2 
participate in relevant cellular functions as for instance, 
stemness, proliferation, survival, adhesion and invasion 
and metabolism [138]. Considering the broad diversity of 
cancers expressing Sox2, the functions and downstream 
targets of Sox2 are likely to be relevant for other cancers. 
Thus, the progressive decrease of p27 levels in tumors will 
Figure 6: Role of the transcriptional regulatory function of p27 in cancer. This scheme summarizes how the decrease of p27 
levels observed in many different types of human tumors participates in tumor progression and malignancy. The decrease of p27 produced 
by oncogenic stimuli induce the deregulation of the expression of genes involved in cellular functions that facilitates the acquisition of 
tumor capabilities that are defined as Hallmarks of cancer. Specifically, by deregulating genes involved in oxidative phosphorylation and 
cell proliferation, genes encoding chemokines and their receptors and genes involved in the generation of ad hoc metastatic niches, p27 
decrease in facilitates tumor progression and malignancy.
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participate in an increased malignancy by deregulating a 
number of genes involved in the acquisition of at least 4 
cancer hallmarks.
Role of p27-mediated transcriptional regulation 
in neurodegeneration
As mentioned above, one of the relevant 
transcriptional programs regulated by p27, identified in the 
expression microarray analysis, is neuron differentiation 
[32]. This is in agreement with results from the two ChIP-
seq analysis reported until now that also identifies neuron 
differentiation as a major biological process regulated by 
p27 [76, 114]. Specifically, in the microarray analysis 
64 genes of this program were deregulated in p27KO 
MEFs, 26 of them up-regulated and 38 down-regulated. 
Interestingly, also 29 genes involved in axon guidance 
were deregulated in p27KO cells. These genes include 
6 semaphorines, 3 ephrins and 4 ephrin receptors. These 
data clearly indicate that p27 has an active role in the 
nervous system. However, the more intriguing results were 
that unexpectedly, several of the transcriptional programs 
regulated by p27 are related to neurodegenerative diseases 
as: Alzheimer (AD), Huntington (HD) and Parkinson 
(PD) [32]. Specifically, in the case of PD the microarrays 
revealed that the expression of 22 genes related to this 
disease are altered in cells lacking p27. Interestingly, only 
two of them are up-regulated whereas the other 20 are 
down-regulated. One of the upregulated genes is SNCA 
encoding α-SYN, a major component of the Lewy’s bodies 
(LB) (protein aggregates in specific neurons of affected 
patients). The presence of LBs is the most relevant 
neuropathological hallmark of PD [139, 140]. These 
results clearly suggest that p27 might be involved in the 
transcriptional regulation of α-SYN. In fact, we have 
recently reported that actually p27 represses the expression 
of α-SYN by a mechanism that involves p130/E2F4 
complexes [92]. These results clearly indicate that p27 
could have a role in the etiology of PD. Moreover, most 
of down-regulated genes in p27KO cells that are related to 
PD encode for proteins belonging to many mitochondrial 
complexes involved in oxidative phosphorylation. Thus, 
the down-regulation of these genes in p27KO cells 
suggests a decrease of oxidative phosphorylation and as 
a consequence and increase in oxidative stress. This can 
be related to mitochondrial dysfunction that is another 
relevant hallmark of PD [140]. Neurons from PD patients 
present a decrease in the activity of the complex I of 
the respiratory chain and this generates oxidative stress. 
Finally, the increased expression of chemokines as CXCL1 
and CXCL5 in p27KO cells might participate in inducing 
inflammation that is another PD hallmark [140]. Thus, the 
decrease of p27 lead to the induction of molecular changes 
that are similar to those observed in PD (Figure 7).
As oxidative stress and mitochondrial dysfunction 
are also involved in the induction of AD and HD [141–
143], the decreased expression of a significant number 
of genes involved in oxidative phosphorylation and 
the increase of chemokine secretion in cells lacking 
p27 also suggest a role of p27 in the induction of these 
diseases. Interestingly, a significant downregulation in 
the expression of ApoE, (~ 15 fold) is also observed in 
p27KO cells. ApoE is a protein involved in the transport 
of cholesterol and in the clearance of beta-amyloid 
(Aβ) peptides from the brain. Aβ peptides derive from 
proteolysis of the amyloid precursor protein (APP). 
The fibrillary form of Aβ is the primary component of 
amyloid plaques found in the brains of AD patients and 
that are a crucial hallmark of AD [144, 145]. As ApoE is 
involved in the main mechanism of eliminating Aβ, the 
strong diminution of ApoE expression in p27KO cells will 
facilitate Aβ accumulation.
Figure 7: Role of the transcriptional regulatory function of Parkinson’s disease (PD). This scheme summarizes how the 
decrease of p27 levels induce molecular changes similar to those observed in neurons of patients affected by PD. The decrease of p27 induced 
by not well known mechanisms (environmental toxic agents?), can deregulate the expression of genes that participate in the induction of 
the main PD Hallmarks. Specifically, of alpha-synuclein (Lewy’s pathology), mitochondrial subunits (mitochondrial dysfunction) and 
chemokines (neuroinflammation).
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Altogether these data strongly suggest a participation 
of p27 in the etiology of these neurodegenerative diseases.
CONCLUSIONS AND PERSPECTIVES
Data accumulated during the last years clearly 
indicate that in addition to its classical role as a regulator 
of cyclin-Cdk activity, p27 also plays a role as a 
transcriptional regulator. This role is mediated by its 
interaction with specific TFs that facilitates its association 
with defined chromatin regions. p27 mainly associate 
with intergenic distal and intronic regions, although it 
also binds to a significant number of gene promoters. 
Up to now, a number of TFs that binds to p27 have been 
reported. It interacts with p130/E2F4 complexes, Ets1, 
Pax5, Ngn2, AHR, Pax4 and MyoD. It also interacts 
with the acetyltransferase and transcriptional co-activator 
PCAF. A mechanistic model of the participation of p27 
in the regulation of p130/E2F4 repressed genes has been 
developed showing that p21 also collaborates in this 
mechanism. In this model the sequential recruitment of 
different cyclin-Cdk complexes on the promoters of target 
genes is accomplished first by p27 and later on by p21. 
In this model p27 and p21 associate with E2F4/p130 by 
its carboxyl moiety while they recruit the cyclin-Cdk 
complexes by the KID domain located at their NH2 half. 
It can be hypothesized that this model could be extended 
to other TFs by postulating that p27 can associate with 
the TF partners by its carboxyl domain and thus in such 
a way binds to the chromatin. By interacting with cyclin-
Cdks by its amino region it facilitates the proximity of the 
Cdk with substrates associated to the chromatin. However, 
the extension of this model to other TFs, still remains to 
be validated. ChIP on chip, ChIP-seq and expression 
microarray analysis have allowed the identification of the 
transcriptional programs regulated by p27. In addition to 
cell cycle progression and functions as mRNA processing 
and splicing, translation and oxidative phosphorylation, 
firstly identified by Chip on chip data, a number of other 
cellular processes as: cell adhesion, cell-signaling, neuron 
differentiation and ion transport have been identified 
by ChIP-seq and expression microarrays. Among genes 
deregulated in p27KO cells there is a number of TFs that 
probably generates subsequent waves of transcription 
that, in this case, would not be directly regulated by p27. 
Interestingly, a reduced number of TFs as Mef2c, Sox6, 
Zfpm2 and Shox2 that have p27-BSs at their vicinity (as 
detected by ChIP), are also deregulated in expression 
microarrays suggesting that they are direct targets of 
p27. They can be subsequently involved in the triggering 
of a second transcriptional wave. Many other TFs that 
do not have p27-BSs in the proximity and that were 
found deregulated in p27KO cells might be involved in 
subsequent transcriptional waves.
Finally, altered levels of p27 can participle in 
different pathologies as cancer and neurodegenerative 
diseases as PD, AD and HD. In the case of cancer, it is 
well known that reduced levels of p27 in human tumors 
are associated with a poor outcome of the patients. The 
increased malignancy in these tumors can be induced by 
transcriptional alteration of p27-TGs involved in different 
cancer hallmarks. Potentially interesting are data indicating 
that p27 might regulate the expression of genes involved 
in different neurodegenerative diseases as for instance 
SNCA, ApoE and genes encoding different subunits of the 
different oxidative-phosphorylation complexes that could 
induce oxidative stress. The putative participation of p27, 
through its transcriptional regulatory role, in the onset and 
progression of these different neurodegenerative diseases 
needs to be extensively studied in the next future.
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